Search results for " patients"
Article
From Darwin to Recombinant Fc Multimers
Perkins emphasized the importance of having a healthy plasma fractionation industry not just for the patients, but also for the donors and the people within the industry. He presented data showing how…
Article
The Affordable Care Act's Impact on Innovation in Biopharma
The ACA, for example, includes demonstration and implementation of new payment and care delivery models for Medicare patients (e.g., accountable care organizations [ACOs]), provisions to better coordi…
Article
Bracing for a Future Wave of Advanced Therapies
Hunt went on to explain that there is significant time, talent, and money being committed to CGTs with the goal of getting these therapies to patients with debilitating, often fatal, diseases or disor…
Article
Roadmap Leads to Innovative Biomanufacturing Strategies
…try has responsibility to bring better, faster, cheaper, and higher quality therapeutics for serving patients. Biomanufacturers are uniquely aware of the challenges faced during development and manuf…
Article
The Bullish Outlook for Biosimilars
Despite being offered at an approximately 20-25% discount, these drugs have failed to make a large impact on the market, largely because their originator counterparts offer greater convenience to pati…
Article
Moving Biosimilars Forward in a Hesitant Market
… interchangeable], much of the time, the comfort level or the hesitancy is there among doctors—and patients—in prescribing the same medicine as that of the innovator. Even though [the biosimilar] is …
Article
Emerging Therapies Test Existing Bioanalytical Methods
Drug developers must understand the complex bioanalytical assays for cell- and gene-therapy drug development programs and ensure that partners have the specialized expertise needed for complex thera…
Article
Taking a “Development-by-Design” Approach to Cell Therapies
Jun 15, 2015
By Agnes Shanley
BioPharm International eBooks
Volume 28, Issue 13
Whether outsourcing or developing cell therapies in-house, success demands a focus on quality, c…
Article
Labeling of Biosimilars
Information on quality is important because it will fulfill the whole purpose of labeling by enabling both physicians and patients to make informed decisions about the safe and effective use of biosim…
Article
Monoclonal Antibodies Key to Unlocking the Biosimilars Market
Education of physicians, pharmacists, and patients by biosimilar manufacturers and strong support for adoption by individual governments is, however, also required if biosimilar mAbs—and the biosimila…